Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
   PubMed Web of Science ®Google Scholar
• Giaquinto AN, Broaddus RR, Jemal A, et al. The changing landscape of gynecologic cancer mortality in the United States. Obstet Gynecol. 2022;139(3):440–442.
   PubMed Web of Science ®Google Scholar
• Clarke MA, Devesa SS, Harvey SV, et al. Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J Clin Oncol. 2019;37:1895–1908.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):463–469.
   PubMed Web of Science ®Google Scholar
• Thomas M, Mariani A, Wright JD, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol. 2008;108(2):293–297.
   PubMed Web of Science ®Google Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–1285.
   PubMed Web of Science ®Google Scholar
• Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380(24):2317–2326.
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2006;24(1):36–44.
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, Casado Herraez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448.
   PubMed Web of Science ®Google Scholar
• McMeekin S, Dizon D, Barter J, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138(1):18–23.
   PubMed Web of Science ®Google Scholar
• Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma Proceedings of the National Academy of Sciences of the United States of America 2013. 110:p. 2916–2921.
   Google Scholar
• Hayes MP, Ellenson LH. Molecular alterations in uterine serous carcinoma. Gynecol Oncol. 2010;116(2):286–289.
   PubMed Web of Science ®Google Scholar
• Bogani G, Ray-Coquard I, Concin N, et al. Uterine serous carcinoma. Gynecol Oncol. 2021;162(1):226–234.
   PubMed Web of Science ®Google Scholar
• Kyo S, Nakayama K. Endometrial cancer as a metabolic disease with dysregulated PI3K signaling: shedding light on novel therapeutic strategies. Int J Mol Sci. 2020;21(17):6073.
   Google Scholar
• Lengyel CG, Altuna SC, Habeeb BS, et al. The potential of PI3K/AKT/mTOR signaling as a druggable target for endometrial and ovarian carcinomas. Curr Drug Targets. 2020;21(10):946–961.
   PubMed Web of Science ®Google Scholar
• Ohmichi M, Hayakawa J, Tasaka K, et al. Mechanisms of platinum drug resistance. Trends Pharmacol Sci. 2005;26(3):113–116.
   PubMed Web of Science ®Google Scholar
• Blake JF, Xu R, Bencsik JR, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012;55(18):8110–8127.
   PubMed Web of Science ®Google Scholar
• Lin J, Sampath D, Nannini MA, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013;19(7):1760–1772.
   PubMed Web of Science ®Google Scholar
• Saura C, Roda D, Roselló S, et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov. 2017;7(1):102–113.
   PubMed Web of Science ®Google Scholar
• Kim S-B, Dent R, Im S-A, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncol. 2017;18(10):1360–1372.
   PubMed Web of Science ®Google Scholar
• Oliveira M, Saura C, Nuciforo P, et al. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019;30(8):1289–1297.
   PubMed Web of Science ®Google Scholar
• Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2021;398(10295):131–142.
   PubMed Web of Science ®Google Scholar
• Wang Q, Peng H, Qi X, et al. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther. 2020;5(1):137.
   PubMed Web of Science ®Google Scholar
• Van Nyen T, Moiola CP, Colas E, et al. Modeling endometrial cancer: past, present, and future. Int J Mol Sci. 2018;19(8):2348.
   Web of Science ®Google Scholar
• Diver EJ, Hernandez SF, Scaltriti M, et al. Targeting HER2 and PI3K in uterine serous cancer. Gynecologic Oncology. 2015;139(3):596.
   Web of Science ®Google Scholar
• Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149.
   PubMed Web of Science ®Google Scholar
• Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol. 2009;113(3):370–373.
   PubMed Web of Science ®Google Scholar
• Morgillo F, Della Corte CM, Diana A, et al. Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. Oncotarget. 2017;8(44):76479–76491.
   PubMedGoogle Scholar
• Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–1967.
   PubMed Web of Science ®Google Scholar
• López-Plana A, Fernández-Nogueira P, Muñoz-Guardiola P, et al. The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. Int J Cancer. 2020;147(4):1163–1179.
   PubMed Web of Science ®Google Scholar
• Dent R, Oliveira M, Isakoff SJ, et al. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2021;189(2):377–386.
   PubMed Web of Science ®Google Scholar
• Farhan M, Wang H, Gaur U, et al. FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci. 2017;13(7):815–827.
   PubMed Web of Science ®Google Scholar
• Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018;8(5):180002.
   PubMed Web of Science ®Google Scholar
• Campbell KJ, Leung HY. Evasion of cell death: a contributory factor in prostate cancer development and treatment resistance. Cancer Lett. 2021;520:213–221.
   PubMed Web of Science ®Google Scholar
• Sun L, Huang Y, Liu Y, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell Death Dis. 2018;9(9):018–0943.
   PubMedGoogle Scholar
• Laterza MM, Ciaramella V, Facchini BA, et al. Enhanced antitumor effect of trastuzumab and duligotuzumab or ipatasertib combination in HER-2 positive gastric cancer cells. Cancers. 2021;13(10):2339.
   Web of Science ®Google Scholar
• Koundouros N, Poulogiannis G. Phosphoinositide 3-Kinase/akt signaling and redox metabolism in cancer. Frontiers in Oncology. 2018;8:160.
   Web of Science ®Google Scholar
• Bekhet OH, Eid ME. The interplay between reactive oxygen species and antioxidants in cancer progression and therapy: a narrative review. Transl Cancer Res. 2021;10(9):4196–4206.
   PubMed Web of Science ®Google Scholar
• Renaudin X. Reactive oxygen species and DNA damage response in cancer. Int Rev Cell Mol Biol. 2021;364:139–161.
   PubMed Web of Science ®Google Scholar
• Mao W, Sun Y, Zhang H, et al. A combined modality of carboplatin and photodynamic therapy suppresses epithelial-mesenchymal transition and matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in HEp-2 human laryngeal cancer cells via ROS-mediated inhibition of MEK/ERK signalling pathway. Lasers Med Sci. 2016;31(8):1697–1705.
   PubMed Web of Science ®Google Scholar
• Mao W, He P, Wang W, et al. Andrographolide sensitizes hep-2 human laryngeal cancer cells to carboplatin-induced apoptosis by increasing reactive oxygen species levels. Anti-Cancer Drugs. 2019;30(7):731–739.
   Web of Science ®Google Scholar
• Yu L, Liu Z, Qiu L, et al. Ipatasertib sensitizes colon cancer cells to TRAIL-induced apoptosis through ROS-mediated caspase activation. Biochem Biophys Res Commun. 2019;519(4):812–818.
   PubMed Web of Science ®Google Scholar
• Stefanou DT, Souliotis VL, Zakopoulou R, et al. DNA damage repair: predictor of platinum efficacy in ovarian cancer? Biomedicines. 2021;10(1):82.
   Web of Science ®Google Scholar
• David-West G, Ernlund A, Gadi A, et al. mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs. Oncotarget. 2018;9(69):33064–33076.
   PubMedGoogle Scholar
• Musa F, Alard A, David-West G, et al. Dual mTORC1/2 inhibition as a novel strategy for the resensitization and treatment of platinum-resistant ovarian cancer. Mol Cancer Ther. 2016;15(7):1557–1567.
   PubMed Web of Science ®Google Scholar
• Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24(4):679–686.
   PubMed Web of Science ®Google Scholar
• Abuzeid WM, Jiang X, Shi G, et al. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest. 2009;119(7):1974–1985.
   PubMed Web of Science ®Google Scholar
• Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori. 2004;90(1):2–8.
   PubMed Web of Science ®Google Scholar
• Barati MT, Lukenbill J, Wu R, et al. Cytoskeletal rearrangement and Src and PI-3K-dependent Akt activation control GABA(B)R-mediated chemotaxis. Cell Signal. 2015;27(6):1178–1185.
   PubMed Web of Science ®Google Scholar
• Catasus L, Gallardo A, Cuatrecasas M, et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol. 2008;21(2):131–139.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Z, Zhang X, et al. A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma. Am J Transl Res. 2016;8(2):719–731.
   PubMed Web of Science ®Google Scholar
• Winder A, Unno K, Yu Y, et al. The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient-derived xenografts of endometrial cancer. Cancer Biol Ther. 2017;18(12):958–964.
   PubMed Web of Science ®Google Scholar
• Yu X, Liu J, Qiu H, et al. Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer. Bosn J Basic Med Sci. 2021;21(2):198–207.
   PubMed Web of Science ®Google Scholar